Temsirolimus
Author:
Publisher
Springer Berlin Heidelberg
Link
http://link.springer.com/content/pdf/10.1007/978-3-642-54490-3_24
Reference34 articles.
1. Aass N, De Mulder HM, Mickisch GHJ et al (2005) Randomized phase II/III trial of interferon alfa-2a with and without 13- cis –retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EOTORC 30951). J Clin Oncol 23:4172–4178
2. Alexandrescu DT, Dasanu CA (2006) Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother 7(18):2481–2493
3. Ansell SM et al (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. A phase 2 trial in the North Central Cancer Treatment Group. Cancer 113(3)
4. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918
5. Chang SM et al (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357–361
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Interplay between Autophagy and Mitochondria in Cancer;International Journal of Molecular Sciences;2024-08-23
2. Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer;2023-08-16
3. Therapeutic potential of natural compounds from herbs and nutraceuticals in spinal cord injury: Regulation of the mTOR signaling pathway;Biomedicine & Pharmacotherapy;2023-07
4. mTORC1-Induced Bone Marrow-Derived Mesenchymal Stem Cell Exhaustion Contributes to the Bone Abnormalities in Klotho-Deficient Mice of Premature Aging;Stem Cells and Development;2023-06-01
5. Can pharmacy students use Wikipedia as a learning resource? Critical assessment of articles on chemotherapeutic drugs;Advances in Physiology Education;2023-06-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3